The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review.
The aim of this systematic review was taken to investigate the efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone for treating androgen-independent prostate cancer (AIPC). Data were collected from different databases independently by three researchers according to the pre-defined inclusion and exclusion criteria. Total three studies were finally included, indicating that docetaxel plus thalidomide exhibited better survival prognosis and greater prostate-specific antigen (PSA) decline than docetaxel alone. There were no significant differences of hematologic toxicities in two regimens, while the frequency of non-hematologic toxicities was higher in patients with docetaxel plus thalidomide. Briefly, the available evidence indicates potential survival advantage in docetaxel plus thalidomide over docetaxel alone.
1] Intensive Care Unit, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China [2] Tumor Invasion Microecological Laboratory, Fujian Medical University, Fuzhou, Fujian 350005, China.
Long
L
Chen
Tumor Invasion Microecological Laboratory, Fujian Medical University, Fuzhou, Fujian 350005, China.
Xianxin
X
Qiu
Department of Chemotherapy, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China.
Rixiong
R
Wang
Department of Chemotherapy, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China.
Xianhe
X
Xie
D000728:Androgens / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D043823:Taxoids / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome
D000728:Androgens; D043823:Taxoids; D000077143:Docetaxel; D013792:Thalidomide